Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept versus epoetin alfa in ESA-naive lower-risk MDS with transfusion-dependent anemia
NL-OMON52493Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) and anaemia comparing Luspatercept with Epoetin alfa (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2020; status: active, not recruiting.
02
Drugs
luspaterceptepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)anaemia
Beyond the preview
Go deeper on NL-OMON52493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52493.